Medlmmune and Tanabe Research Laboratories / Mitsui Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer

Medlmmune and Tanabe Research Laboratories / Mitsui Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer

San Diego, CA /Osaka, JPN/Gaithersburg, MD September 23, 2015 – MedImmune, the global biologics research and development arm of AstraZeneca, and Tanabe Research Laboratories U.S.A., Inc. (TRL), a subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced that they have entered into a strategic collaboration and licensing agreement under which TRL will use MedImmune’s pyrrolobenzodiazepine […]

Read More »